Evidence map›Paper›PMID 37759044›Full record

ArticleClinical rheumatology2024

Response to: comment on "validation and predictive capacity of a dutch version of the FLARE-RA questionnaire within the context of a TNFi-tapering trial".

Michaël Doumen, Delphine Bertrand, Sofia Pazmino, Diederik De Cock, Veerle Stouten, Johan Joly, René Westhovens, Patrick Verschueren

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Michaël DoumenDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. michael.doumen@kuleuven.be.ORCID 0000-0001-6073-7635
Delphine BertrandDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Sofia PazminoDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Diederik De CockBiostatistics and Medical Informatics Research Group, Department of Public Health, Vrije Universiteit Brussel, Brussels, Belgium.
Veerle StoutenDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Johan JolyDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
René WesthovensDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Patrick VerschuerenDepartment of Development and Regeneration, Skeletal Biology and Engineering Research Centre, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antirheumatic AgentsEtanerceptHumansTumor Necrosis Factor-alphaAntirheumatic AgentsEtanerceptTumor Necrosis Factor-alpha

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.